Millipore Sigma Vibrant Logo

481908 Nicotinamide Phosphoribosyltransferase Inhibitor, FK866 - CAS 658084-64-1 - Calbiochem

View Products on Sigmaaldrich.com
481908
Visualizza prezzi e disponibilità

Panoramica

Replacement Information

Tabella delle specifiche principali

CAS #Empirical Formula
658084-64-1C₂₄H₂₉N₃O₂

Prezzi e disponibilità

Numero di catalogo DisponibilitàConfezionamento Qtà/conf Prezzo Quantità
481908-2MG
Verifica della disponibilità in corso...
Disponibilità limitata
Disponibilità limitata
A magazzino 
Fuori produzione
Disponibili quantità limitate
La disponibilità deve essere confermata
    Prodotti rimanenti: riceverà un nostro avviso
      Prodotti rimanenti: riceverà un nostro avviso
      Will advise
      Contatti il Servizio Clienti
      Contact Customer Service

      2 mg
      Ricerca del prezzo in corso...
      Non è stato possibile trovare il prezzo
      La quantità minima deve essere un multiplo di
      Maximum Quantity is
      Al termine dell'ordine Maggiori informazioni
      Lei ha salvato ()
       
      Richiedi il prezzo
      Description
      OverviewA cell-permeable pyridinylacrylamide compound that acts as a selective, allosteric NAPRT/NAMPT (nicotinamide phosphoribosyltransferase) inhibitor (Ki = 0.4 nM for the enzyme/substrate complex; Ki = 0.3 nM for the free enzyme), while exhibiting no effect toward NPRT (nicotinic acid phosphoribosyltransferase) activity (82% inhibition of NAPRT activity at 10 nM vs no inhibition of NPRT activity at 1 µM in K-562 extract). FK866 treatment is shown to induce cell death by depleting NAD+ (Cat. Nos. 481911 & 481915) in HepG2 and NIH-3T3 cultures (by >95% after 24 h treatment of 10 nM FK866), likewise the addition of exogenous NAD+ is demonstrated to rescue NIH-3T3 and SH-SY5Y from FK866-induced NAD+-depletion and cell death.
      Catalogue Number481908
      Brand Family Calbiochem®
      SynonymsNAPRT Inhibitor, (E)-N-(4-(1-Benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide, NAMPT Inhibitor, APO866, NAMPTase Inhibitor I, PBEF Inhibitor I, Visfatin Inhibitor I
      References
      ReferencesFormentini, L., et al. 2009. Biochem. Pharmacol. 77, 1612.
      Nakahata, Y., et al. 2009. Science 324, 654.
      Ramsey. K.M., et al. 2009. Science 324, 651.
      Billington, R.A., et al. 2008. J. Biol. Chem. 283, 6367.
      Hasmann, M. and Schemainda, I., 2003. Cancer Res. 63, 7436.
      Product Information
      CAS number658084-64-1
      FormColorless to yellow liquid
      FormulationSupplied as a 50 mM (2 mg/102.17 µl) solution in DMSO.
      Hill FormulaC₂₄H₂₉N₃O₂
      Chemical formulaC₂₄H₂₉N₃O₂
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Purity≥97% by HPLC
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Numero di catalogo GTIN
      481908-2MG 04055977225532

      Documentation

      Nicotinamide Phosphoribosyltransferase Inhibitor, FK866 - CAS 658084-64-1 - Calbiochem MSDS

      Titolo

      Scheda di sicurezza (MSDS) 

      Nicotinamide Phosphoribosyltransferase Inhibitor, FK866 - CAS 658084-64-1 - Calbiochem Certificati d'Analisi

      TitoloNumero di lotto
      481908

      Riferimenti bibliografici

      Panoramica delle referenze
      Formentini, L., et al. 2009. Biochem. Pharmacol. 77, 1612.
      Nakahata, Y., et al. 2009. Science 324, 654.
      Ramsey. K.M., et al. 2009. Science 324, 651.
      Billington, R.A., et al. 2008. J. Biol. Chem. 283, 6367.
      Hasmann, M. and Schemainda, I., 2003. Cancer Res. 63, 7436.
      Scheda tecnica

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision06-May-2020 JSW
      SynonymsNAPRT Inhibitor, (E)-N-(4-(1-Benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide, NAMPT Inhibitor, APO866, NAMPTase Inhibitor I, PBEF Inhibitor I, Visfatin Inhibitor I
      DescriptionA cell-permeable pyridinylacrylamide compound that acts as a selective, allosteric NAPRT/NAMPT (nicotinamide phosphoribosyltransferase) inhibitor (Ki = 0.4 nM for the enzyme/substrate complex; Ki = 0.3 nM for the free enzyme), while exhibiting no effect toward NPRT (nicotinic acid phosphoribosyltransferase) activity (82% inhibition of NAPRT activity at 10 nM vs no inhibition of NPRT activity at 1 µM in K-562 extract). FK866 treatment is shown to induce cell death by depleting NAD+ (Cat. Nos. 481911 & 481915) in HepG2 and NIH-3T3 cultures (by >95% after 24 h treatment of 10 nM FK866), likewise the addition of exogenous NAD+ is demonstrated to rescue NIH-3T3 and SH-SY5Y from FK866-induced NAD+-depletion and cell death.
      FormColorless to yellow liquid
      FormulationSupplied as a 50 mM (2 mg/102.17 µl) solution in DMSO.
      Intert gas (Yes/No) Packaged under inert gas
      CAS number658084-64-1
      Chemical formulaC₂₄H₂₉N₃O₂
      Structure formulaStructure formula
      Purity≥97% by HPLC
      SolubilityDMSO (100 mg/ml)
      Storage Protect from light
      +2°C to +8°C
      Do Not Freeze Ok to freeze
      Toxicity Standard Handling
      ReferencesFormentini, L., et al. 2009. Biochem. Pharmacol. 77, 1612.
      Nakahata, Y., et al. 2009. Science 324, 654.
      Ramsey. K.M., et al. 2009. Science 324, 651.
      Billington, R.A., et al. 2008. J. Biol. Chem. 283, 6367.
      Hasmann, M. and Schemainda, I., 2003. Cancer Res. 63, 7436.